IACT Health is proud to announce the success of a clinical trial in partnership with Sunovion Pharmaceuticals. Due to the success of IACT’s clinical trial, a new long-acting nebulizer inhaler, Lonhala Magnair, has been approved for long-term maintenance treatment in patients with COPD, including bronchitis and emphysema.

This approval provides physicians and patients with the first nebulized LAMA as an additional therapeutic option for the management of COPD.